Comparing Effectiveness Rituximab (Mabthera®) to Other Second-line Biologics for Rheumatoid Arthritis Treatment in Patients Refractory to or Intolerant of First-line Anti-tumor Necrosis Factor Agent: An Observational Study
Yong-Wook Park(Chonnam National University Hospital), Sang‐Heon Lee(Soonchunhyang University), Ji Seon Oh(Ministry of Food and Drug Safety), Yeon-Ah Lee(Kyung Hee University), Jung‐Yoon Choe(Daegu Catholic University), Ki‐Jo Kim(The Catholic University of Korea St. Vincent's Hospital), Bo Young Yoon(Inje University Ilsan Paik Hospital), Min‐Chan Park(Yonsei University), Sang-Hyon Kim(Inje University Haeundae Paik Hospital), Seongho Kim(Wayne State University), Jinseok Kim(National Institutes of Health), Hyung-In Yang(Kyung Hee University Hospital at Gangdong), Wan‐Uk Kim(Catholic University of Korea)
Cited by 3
Related Papers
High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry
|Nature Genetics|2016|269
Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus
|The Journal of Immunology|2014|189
Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus
|Annals of the Rheumatic Diseases|2020|183
Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer
|Oncotarget|2016|133
Circulating mucosal-associated invariant T cell levels and their cytokine levels in healthy adults
|Experimental Gerontology|2013|132